pharmaphorum

Pathos AI signs two cancer deals with Alphamab and AZ

Pathos AI has added to its pipeline of cancer drugs by licensing a bispecific antibody-drug conjugate (ADC) for solid tumours ...

Pathos AI to license experimental breast cancer drug from China's Jiangsu Alphamab Biopharmaceutical

Aug 4 (Reuters) - New York City-based Pathos AI will pay $125 million upfront to a subsidiary of Alphamab Oncology for rights ...
Las Vegas Sun

Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC

Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced a licensing agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
TMCnet

Pathos AI Enters Collaboration and Co-Exclusive Licensing Agreement to Advance Novel ERa PROTAC for ER+ Breast Cancer into the Clinic

Foundry utilizes thousands of AI agents working in parallel, powered by the Pathos Oncology Foundation Model. These agents analyze complex biological, clinical, and real-world data to intelligently ...
FierceBiotech

Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact

Pathos AI has agreed to pay $125 million for a bispecific antibody-drug conjugate (ADC) from Alphamab Oncology, while adding another Big Pharma partner in the form of AstraZeneca. The deal with ...
AASTOCKS.com

ALPHAMAB-B (09966.HK) Grants Exclusive Development Rights of JSKN016 to Pathos AI in Deal Worth Nearly USD2.1 Billion

ALPHAMAB-B (09966.HK) announced that its wholly-owned subsidiary Jiangsu Alphamab Biopharmaceuticals entered into a licensing ...